TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05834660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Alternatives for Teens and Youth-Acute for Schools (SAFETY-A for Schools)
Description: SAFETY-A is a brief, family centered, cognitive-behavioral approach to therapeutic risk assessment and safety planning that can be delivered via school-based providers. The intervention is delivered in one session during which the youth at risk for suicidal behavior works with the provider to identify strengths, supports, understand emotional antecedents and warning signs, identify alternative coping behaviors and thoughts, and ways to keep the environment safe. Youth and families receive follow-up contacts by phone at 1, 2, and 4 weeks after the SAFETY-A session. The primary focus is on the therapeutic mechanisms of hope, reduced intensity of suicidal urges, increased confidence in ability to keep safe. Adaptation of SAFETY-A for Schools will target mechanisms that are presumed to drive disparities in mental health service use among Asian American and Latinx youth: (1) trust in mental health services, (2) internalized stigma, and (3) comfort communicating distress.
Study: NCT05407402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter yoga practice
Description: To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: watching funny videos
Description: To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
Study: NCT04616378

Intervention type: OTHER
Group type: OTHER
Intervention: Phase 2 Prescribed Prosthesis
Description: Everyday used prosthesis that was prescribed by their physician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 2 Robotic Prosthetic Leg
Description: The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 3 No Prosthesis
Description: No prosthetic device is attached.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 3 Robotic Prosthetic Leg
Description: The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Phase 3 Prescribed Prosthesis
Description: Everyday used prosthesis that was prescribed by their physician.
Study: NCT04842266

Intervention type: DEVICE
Intervention: IlluminOss pelvic implant for oncologic indication
Description: Impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis

Intervention type: DEVICE
Intervention: IlluminOss pelvic implant for geriatric trauma indication
Description: Pelvic fragility fracture in a geriatric patients (age 65 or older)
Study: NCT05077722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Garmin
Description: A smartwatch device that measures subjects level of activity, heartrate, respirations and quality of your sleep at night. Artificial intelligence will be applied to analyze all the data over the course of 12 weeks to monitor and attempt to predict the onset of tantrums or disruptive behavior. Subjects are required to wear the watch at least 70% of the day and night each day for 70% of days during 12 weeks of treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Garmin
Description: A smartwatch device that measures subjects level of activity, heartrate, respirations and quality of your sleep at night. Artificial intelligence will be applied to analyze all the data over the course of 12 weeks to monitor and attempt to predict the onset of tantrums or disruptive behavior. Subjects are required to wear the watch at least 70% of the day and night each day for 70% of days during 12 weeks of treatment.
Study: NCT04540354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Description: Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT)
Description: Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Description: An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed.
Study: NCT06220188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA I&T
Description: 2 cycles (3 GBq in first cycle and 6 GBq in the second cycle) of \[177Lu\]Lu-PSMAI\&T radioligand therapy at 6-week intervals
Study: NCT05833061

Intervention type: OTHER
Intervention: The Stroke-Specific Quality of Life (SS-QoL) scale
Description: The Stroke-Specific Quality of Life (SS-QoL) scale is a questionnaire-based tool that is used to assess the quality of life of individuals who have experienced a stroke. It was developed to evaluate the impact of stroke on various domains of life, including physical, psychological, and social aspects. The SS-QoL scale contains 49 items, which are organized into 12 domains such as mobility, self-care, work/productivity, language, social roles, and emotional well-being. The scale has been validated and is widely used by healthcare professionals and researchers to assess the effectiveness of interventions and treatments for stroke patients, as well as to evaluate the long-term impact of stroke on their quality of life.

Intervention type: OTHER
Intervention: The Stroke Self-Efficacy Questionnaire (SSEQ)
Description: The Stroke Self-Efficacy Questionnaire (SSEQ) is a tool used to measure an individual's perceived self-efficacy or confidence in managing the consequences of a stroke. It consists of 13 items that assess an individual's ability to manage various stroke-related challenges, such as physical, emotional, and social difficulties. The SSEQ is designed to help healthcare professionals and researchers understand how an individual's perceived self-efficacy influences their ability to cope with the consequences of a stroke and manage their recovery effectively. By measuring an individual's perceived self-efficacy, the SSEQ can help identify areas where additional support and interventions may be needed to improve their overall recovery and quality of life.
Study: NCT05906550

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vascular access monitoring
Description: Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy. Patients will be referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vascular access monitoring
Description: Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy. Patients will be referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vascular access blood flow measurement
Description: Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume \<500mL/min.
Study: NCT06508424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PulseOn
Description: PulseOn - 1 week washout period between interventions 75g crackers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wheat flour control
Description: Control -1 week washout period between interventions 75g crackers
Study: NCT06004765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10mg/d \*21 days, 28 days for 1 course

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2/d\*5 days, 28 days for 1 course
Study: NCT05192681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
Study: NCT04922008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine and trastuzumab
Description: In IRIS-C cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given capecitabine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine and trastuzumab
Description: In IRIS-4 cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given vinorelbine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
Study: NCT04918433

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional anaesthesia
Description: Regional anaesthesia for sternotomy incision for congenital cardiac surgery
Study: NCT05894135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG2109 100mg
Description: One tablet of BG2109 100mg , oral , once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG2109 200mg
Description: One tablet of BG2109 200mg, oral , once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT(E2 1 mg / NETA 0.5 mg)
Description: One tablet of ABT(E2 1 mg / NETA 0.5 mg), oral, once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG2109 100mg Placebo
Description: One tablet of BG2109 100mg Placebo, oral , once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BG2109 100mg Placebo
Description: One tablet of BG2109 100mg Placebo, oral , once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG2109 200mg Placebo
Description: One tablet of BG2109 200mg Placebo, oral , once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BG2109 200mg Placebo
Description: One tablet of BG2109 200mg Placebo, oral , once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT Placebo
Description: One tablet of ABT Placebo, oral, once-daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT Placebo
Description: One tablet of ABT Placebo, oral, once-daily
Study: NCT06199375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine treatment
Description: The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine treatment
Description: The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation training
Description: The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation training
Description: The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
Study: NCT06199375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified mirror therapy
Description: The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
Study: NCT05541406

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Proud & Empowered
Description: Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proud & Empowered
Description: Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
Study: NCT05111431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride Nasal Spray
Description: In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine hydrochloride nasal spray blank preparation
Description: In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
Study: NCT05425498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: 12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model.
Study: NCT05575986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: Hetrombopag Olamine 7.5mg orally, once a day, for 14 days. This product should be taken on an empty stomach, 2 hours after oral administration before eating, avoid taking it with meals.
Study: NCT04868162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003
Description: Administered intravenously
Study: NCT05276401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Bisphosphocin Topical Gel
Description: Topical Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Gel
Description: Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Bisphosphocin Topical Gel
Description: Topical Gel
Study: NCT06544785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Oral Product
Description: Zanubrutinib drug product is supplied as 80 mg strengths in capsules for oral administration.~In both arms A and B, zanubrutinib 320 mg will be taken qDay with or without food. Patients will take zanubrutinib with water at approximately the same time every day.
Study: NCT05581420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate
Description: Patients randomized in the oral group, will all be prescribed ferrous fumarate 200 mg d.d. for the first 4 weeks. Then, depending on their iron status, 100 mg d.d. for the following 12 weeks or 4 more weeks 200 mg d.d. followed by 4 weeks 100 mg d.d.. If iron levels are still too low after 12 weeks, the intervention has failed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MonoFer
Description: Study patients will be treated with intravenous iron. The brand name of the iv iron is dependent on the hospital policy and the doses will be according to recommended guidelines (weight of patient). Iv iron is intramural medication without add-on status and needs infusion at daycare.
Study: NCT06544785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Oral Product
Description: Zanubrutinib drug product is supplied as 80 mg strengths in capsules for oral administration.~In both arms A and B, zanubrutinib 320 mg will be taken qDay with or without food. Patients will take zanubrutinib with water at approximately the same time every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Each dose of obinutuzumab is 1000 mg administered intravenously, per institutional standards, with the exception of the first infusion in Cycle 2 (arm A) or Cycle 13 (arm B). It is recommended that the initial 1000 mg dose be administered over Day 1 (100 mg) and Day 2 (900 mg). For subjects who tolerate the initial 100 mg dose well and required no dose interruption or modification of the infusion rate, the treating physician may opt to administer the remaining 900 mg on Day 1.~Arm A: patients will receive obinutuzumab on days 1 (100 mg), 2 (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 2 of zanubrutinib treatment, and on the day 1 of cycles 3-7 (1000 mg).~Arm B: patients will receive obinutuzumab on days 1 (100 mg), 2 ( (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 13 of zanubrutinib treatment, and on the day 1 of cycles 14-18 (1000 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Each dose of obinutuzumab is 1000 mg administered intravenously, per institutional standards, with the exception of the first infusion in Cycle 2 (arm A) or Cycle 13 (arm B). It is recommended that the initial 1000 mg dose be administered over Day 1 (100 mg) and Day 2 (900 mg). For subjects who tolerate the initial 100 mg dose well and required no dose interruption or modification of the infusion rate, the treating physician may opt to administer the remaining 900 mg on Day 1.~Arm A: patients will receive obinutuzumab on days 1 (100 mg), 2 (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 2 of zanubrutinib treatment, and on the day 1 of cycles 3-7 (1000 mg).~Arm B: patients will receive obinutuzumab on days 1 (100 mg), 2 ( (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 13 of zanubrutinib treatment, and on the day 1 of cycles 14-18 (1000 mg).
Study: NCT06004765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2/d\*5 days, 28 days for 1 course
Study: NCT06242366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Intervention 2 phases Phases 1) In-hospital period (4 times and 30-60 mins/times) intervention includes Stroke education, Rehabilitation, environmental management, and complication prevention. Intervention participants will receive a booklet (choose between hard copy or electronic copy) self-care for stroke patients, Rehabilitation clip, and Self-care record form.~Phases 2) after hospital discharge 5 times (first times within 24 hours after hospital discharge) and (second-fifth time: 1 time/weekly)15-30 mins/times by Line Application for repeat and following education, rehabilitation complication prevention and finding limit to self-care management.
Study: NCT05033886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT05801146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection [HG102]
Description: Single administration, Day 0, 20 units
Study: NCT05911867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination of mobilization with movement and muscle energy techniques
Description: The examiner passively abducts the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: muscle energy techniques Interventions:
Description: The examiner passively abduct the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds. The examiner then instruct the participant to attempt to horizontally adduct the test arm at 25% of their maximal effort while the examiner applied manual resistance at the distal humerus to create an isometric contraction lasting five seconds. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobilization with movement
Description: Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range.
Study: NCT05801146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: Single administration, Day 0, 20 units
Study: NCT04787783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web based preoperative assessment
Description: Preoperative assessment conducted through a web based application